Announcements Trials
Browse Landscape

Status

Recruiting 5Completed 2Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 186Observational 8Expanded_access 1

Sponsor

Cancer Type

Thoracic 3Dermatologic 3Tumor-Agnostic 1Other 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Sexual Dysfunction, Physiological 1PROMs 1Neoplasms 1Locally Advanced Melanoma 1Eunuchism 1Erectile Dysfunction 1Cutaneous Squamous Cell Carcinoma (CSCC) 1Carcinoma, Basal Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Observational × cemiplimab × Clear all
NCT05363319 2026-05-13

CEMI-LUNG

Regeneron Pharmaceuticals

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT07223411 2025-11-26

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

University of Pittsburgh

Recruiting
20 enrolled
Dermatologic

Locally Advanced Melanoma

NCT03836105 2025-10-15

CASE

Regeneron Pharmaceuticals

Completed
287 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07064330 2025-09-10

NGF-GRACE

Instituto de Investigación Biomédica de Salamanca

Recruiting
30 enrolled
Dermatologic

Cutaneous Squamous Cell Carcinoma (CSCC)

NCT07061379 2025-09-03

PROMOTING

IRCCS San Raffaele

Recruiting
144 enrolled

PROMs

NCT06532149 2024-08-09

EROS

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Recruiting
80 enrolled
OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05302297 2022-12-13

TOSCA

Sanofi

Completed
305 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡